HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Wednesday, 30 November 2016

Cochrane Collaboration Issue 11, 2016…

….is complete.  The website lists protocols and methodology papers as well, but we’ll just flag up the notable reviews; these being……
  • Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
  • Adjuvant platinum‐based chemotherapy for early stage cervical cancer
  • Gene therapy for sickle cell disease
  • Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
  • Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease
  • Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)

Posted by at